Ardelyx ARDX Stock
Ardelyx Price Chart
Ardelyx ARDX Financial and Trading Overview
| Ardelyx stock price | 6.52 USD |
| Previous Close | 4.02 USD |
| Open | 3.95 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 3000 |
| Day's Range | 3.8 - 3.98 USD |
| 52 Week Range | 0.51 - 5.13 USD |
| Volume | 4.12M USD |
| Avg. Volume | 5.92M USD |
| Market Cap | 840.69M USD |
| Beta (5Y Monthly) | 1.19683 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.21 USD |
ARDX Valuation Measures
| Enterprise Value | 776.04M USD |
| Trailing P/E | N/A |
| Forward P/E | -39.2 |
| PEG Ratio (5 yr expected) | -0.32 |
| Price/Sales (ttm) | 13.331818 |
| Price/Book (mrq) | 6.7008553 |
| Enterprise Value/Revenue | 12.307 |
| Enterprise Value/EBITDA | -14.149 |
Trading Information
Ardelyx Stock Price History
| Beta (5Y Monthly) | 1.19683 |
| 52-Week Change | 590.14% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.13 USD |
| 52 Week Low | 0.51 USD |
| 50-Day Moving Average | 4.19 USD |
| 200-Day Moving Average | 2.81 USD |
ARDX Share Statistics
| Avg. Volume (3 month) | 5.92M USD |
| Avg. Daily Volume (10-Days) | 3.98M USD |
| Shares Outstanding | 214.46M |
| Float | 198.32M |
| Short Ratio | 2.85 |
| % Held by Insiders | 1.50% |
| % Held by Institutions | 41.00% |
| Shares Short | 17.15M |
| Short % of Float | 8.14% |
| Short % of Shares Outstanding | 8.00% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -104.51% |
| Operating Margin (ttm) | -88.51% |
| Gross Margin | 39.24% |
| EBITDA Margin | -86.98% |
Management Effectiveness
| Return on Assets (ttm) | -20.14% |
| Return on Equity (ttm) | -69.51% |
Income Statement
| Revenue (ttm) | 63.06M USD |
| Revenue Per Share (ttm) | 0.36 USD |
| Quarterly Revenue Growth (yoy) | 2329.29% |
| Gross Profit (ttm) | 15.54M USD |
| EBITDA | -54849000 USD |
| Net Income Avi to Common (ttm) | -65909000 USD |
| Diluted EPS (ttm) | -0.35 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 130.37M USD |
| Total Cash Per Share (mrq) | 0.61 USD |
| Total Debt (mrq) | 35.69M USD |
| Total Debt/Equity (mrq) | 28.46 USD |
| Current Ratio (mrq) | 2.649 |
| Book Value Per Share (mrq) | 0.585 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -87219000 USD |
| Levered Free Cash Flow (ttm) | -26368500 USD |
Profile of Ardelyx
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 400 Fifth Avenue |
| ZIP | 02451 |
| Phone | 510 745 1700 |
| Website | https://www.ardelyx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 133 |
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Q&A For Ardelyx Stock
What is a current ARDX stock price?
Ardelyx ARDX stock price today per share is 6.52 USD.
How to purchase Ardelyx stock?
You can buy ARDX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ardelyx?
The stock symbol or ticker of Ardelyx is ARDX.
Which industry does the Ardelyx company belong to?
The Ardelyx industry is Biotechnology.
How many shares does Ardelyx have in circulation?
The max supply of Ardelyx shares is 251.95M.
What is Ardelyx Price to Earnings Ratio (PE Ratio)?
Ardelyx PE Ratio is now.
What was Ardelyx earnings per share over the trailing 12 months (TTM)?
Ardelyx EPS is -0.3 USD over the trailing 12 months.
Which sector does the Ardelyx company belong to?
The Ardelyx sector is Healthcare.
Ardelyx ARDX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Biotechnology Total Retu XNBI | 4501.69 USD — |
-2.14
|
— — | 4479.13 USD — | 4578.05 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 2160.36 USD — |
-2.45
|
— — | 2147.48 USD — | 2200.33 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4195.13 USD — |
-2.14
|
— — | 4174.1 USD — | 4266.29 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}